Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069004 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL16680566 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL31001881 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL16680564 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL2072006 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL24927723 | 1.00 | HSD17B10 (0.53) | HSD17B10BTKSMN1; SMN2HPGDRECQL | |
| SCHEMBL31068869 | 0.88 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL23694162 | 0.88 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL23694159 | 0.88 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL15491795 | 0.88 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | HSD17B10 4502/4885BTK 3299/4885SMN1; SMN2 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.